Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Improvements in Fatigue Correlate with Changes in Clinical and Hematological Outcomes: Post Hoc Analyses from the Pegasus Study

David Cella, PhD, William R. Lenderking, PhD, Sujata P. Sarda, PhD, Scott B. Baver, PhD, Mohamed Hamdani, MS, Ray Hsieh, MS, Shannon Shaffer, MS, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142354

Published: 2020

Journal Articles

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Giselle K. Perez, PhD, Fangxin Hong, PhD, Andrew M. Evens, DO,MMSc, Thomas M. Habermann, MD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Puneet S. Cheema, MD, Philip A. Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Julie E. Chang, MD, David Cella, PhD, Brad S. Kahl, MD, Lynne I. Wagner, PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-140502

Published: 2020

Journal Articles

Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial

David Cella, PhD, Ellen Ritchie, MD, Arnaud Pigneux, MD PhD, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V. Shah, MPH

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134389

Published: 2020

Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3850.

https://doi.org/10.1182/blood-2019-123790

Published: 2019

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

David Cella, PhD, Jan McKendrick, Harrison Davis, Ravi Vij, MBBS, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2190.

https://doi.org/10.1182/blood-2019-122668

Published: 2019

Journal Articles

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Ellen K. Ritchie, MD, David Cella, PhD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 1332.

https://doi.org/10.1182/blood-2019-123779

Published: 2019

Journal Articles

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Eek, PhD, Cristina Ivanescu, PhD, Leanne Kool-Houweling, MSc, David Cella, PhD

Blood (2019) 134 (Supplement_1): 4763.

https://doi.org/10.1182/blood-2019-123056

Published: 2019

Journal Articles

Patient-Reported Outcomes Validation of the FACT-Leu in Acute Myeloid Leukemia: A Review of Baseline Characteristics in AML2002

Jianming He, PhD, Renee Pierson, MBA, Christina Loefgren, MD PhD, David Cella, PhD

Blood (2018) 132 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2018-99-114635

Published: 2018

Journal Articles

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Gordon Cook, David Cella, PhD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Brian GM Durie, MD, Hartmut Goldschmidt, MD, David J. Kuter, MD, Philippe Moreau, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2018-99-112081

Published: 2018

Journal Articles

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Clara Chen, PhD BS, MS, Kim Cocks, Jeffrey McDonald, Erin Mann, Mariana Sacchi, David Cella, PhD

Blood (2017) 130 (Supplement 1): 3441.

https://doi.org/10.1182/blood.V130.Suppl_1.3441.3441

Published: 2017

Journal Articles

An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy

Brian Durie, MD, David J Kuter, MD DPhil, Catherine Davis, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Hartmut Goldschmidt, Ravi Vij, Sergey Popov, David Cella, PhD, Gordon Cook, MD PhD

Blood (2016) 128 (22): 2403.

https://doi.org/10.1182/blood.V128.22.2403.2403

Published: 2016

Journal Articles

What Are the Most Important Symptoms and Concerns of Patients with Indolent Non-Hodgkin's Lymphoma? Content Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18)

Karen Kaiser, PhD, Sara Shaunfield, PhD, Kimberly Webster, MA, Karen Keating, MBA, Lara Boyken, Sara Duffey, Jessica Yarber, MD, David Cella, PhD

Blood (2016) 128 (22): 4792.

https://doi.org/10.1182/blood.V128.22.4792.4792

Published: 2016

Journal Articles

Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Ishan Hirji, Kim Cocks, Jeffrey McDonald, Erin Mann, Kazunobu Kato, MD, David Cella, PhD

Blood (2016) 128 (22): 1831.

https://doi.org/10.1182/blood.V128.22.1831.1831

Published: 2016

Journal Articles

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

Gordon Cook, MD PhD, David Cella, PhD, Brian Durie, MD, Hartmut Goldschmidt, MD, David Kuter, MD DPhil, Philippe Moreau, Ravi Vij, MD MBBS, Catherine Davis, Abderrahim Oukessou, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Sergey Popov, Antonio Palumbo, MD

Blood (2015) 126 (23): 2093.

https://doi.org/10.1182/blood.V126.23.2093.2093

Published: 2015

Journal Articles

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

Ravi Vij, MD, Mehdi M. Moezi, MD, Robin Foà, MD, Gordon Cook, MD, PhD, Antonio Palumbo, MD, Hakan Kaya, MD, Brian Durie, MD, David Cella, PhD, Lieven Annemans, PhD, Yun Su, MD, Pralay Mukhopadhyay, PhD, Trong K. Le, MPH, MS, Maria Teresa Petrucci, MD

Blood (2013) 122 (21): 1964.

https://doi.org/10.1182/blood.V122.21.1964.1964

Published: 2013

Journal Articles

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Jennifer L Beaumont, MS, Cindy Nowinski, MD PhD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Rick E. Blakesley, PhD, Neil J. Gallagher, MD, PhD, James Burns, MS, David Cella, PhD

Blood (2011) 118 (21): 1025.

https://doi.org/10.1182/blood.V118.21.1025.1025

Published: 2011

Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD

Blood (2011) 118 (21): 4184.

https://doi.org/10.1182/blood.V118.21.4184.4184

Published: 2011

Journal Articles

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Jennifer L Beaumont, MS*, John Coombs, PharmD, MBA*, amsi Bollu, V, PhD, MBA*, Richard C. Woodman, MD, David Cella, PhD*

Blood (2010) 116 (21): 3826.

https://doi.org/10.1182/blood.V116.21.3826.3826

Published: 2010

Journal Articles

Disease Burden and Treatment Impact Associated with Myelodysplastic Syndromes: Preliminary Findings From a Web-Based Survey.

Alan F List, MD, Susan Mathias, MPH, Ross D. Crosby, PhD, Kathy Heptinstall, RN, BSN, David Cella, PhD

Blood (2009) 114 (22): 4522.

https://doi.org/10.1182/blood.V114.22.4522.4522

Published: 2009

Journal Articles

Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.

Robert A. Brodsky, MD, Petra Muus, MD, PhD, Ulrich Dührsen, DM, Anita Hill, MB, MD, Monica Bessler, MD, PhD, Steven Coutre, MD, Raquel De Paz, MD, Tibor Moskovits, MD, Ryotaro Nakamura, MD, Eric Van den Neste, MD, Alberto Zanella, MD, Kerry Quinn-Senger, PhD, Henk-Andre Kroon, MD, David Cella, PhD

Blood (2006) 108 (11): 3770.

https://doi.org/10.1182/blood.V108.11.3770.3770

Published: 2006

NARROW

Improvements in Fatigue Correlate with Changes in Clinical and Hematological Outcomes: Post Hoc Analyses from the Pegasus Study

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

Patient-Reported Outcomes Validation of the FACT-Leu in Acute Myeloid Leukemia: A Review of Baseline Characteristics in AML2002

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy

What Are the Most Important Symptoms and Concerns of Patients with Indolent Non-Hodgkin's Lymphoma? Content Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18)

Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Disease Burden and Treatment Impact Associated with Myelodysplastic Syndromes: Preliminary Findings From a Web-Based Survey.

Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only